Newsletters and Deep Dive digital magazine
Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following
Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.
In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.
These days, real-world data collection is in vogue and not hard to come by in healthcare research.